What We Do

Research

To date, the registry has collected and organized data from 2,700 families who are at high risk for familial ovarian cancer. The data is used to monitor patterns and trends and plays an important role in research to identify the underlying genetic causes of ovarian cancer. Research teams at Roswell Park Comprehensive Cancer Center (where the registry is housed) and across the globe use the data collected by the Familial OCR to seek better methods for detecting, treating, curing and eventually preventing familial ovarian cancer.

Registry-related research projects currently underway

Some inherited gene mutations, such as BRCA1 or BRCA2, increase ovarian and breast cancer risk.  Roswell Park researchers have been using registry information from families who have tested negative for BRCA1 and BRCA2 to conduct extended targeted sequencing of genes known to function in a fashion similar to BRCA1 and BRCA2 hoping to identify new gene mutations that can be targeted for routine high risk testing.

Roswell Park Comprehensive Cancer Center’s Center for Personalized Medicine is currently sequencing the genes of registry members whose BRCA status is unknown or negative to identify new high-risk genes.

Partners

The Familial OCR partners with other organizations that are also focused on ovarian cancer research. Together, we have made several important observations that have been published in peer-reviewed journals.

The registry is grateful to work with the following medical and research organizations in its continued mission to ensure the world’s top research teams can continue their progress seeking better methods for detecting, treating, curing and eventually preventing familial ovarian cancer.

OVARIAN CANCER ASSOCIATION CONSORTIUM (OCAC)

OCAC is a forum of investigators of case-control studies of ovarian cancer, formed in April 2005. Many groups are conducting studies with the aim of identifying genes that may be related to the risk of ovarian cancer. The aim of the group is to combine data from many studies, to provide a reliable assessment of the risks associated with these genes.

CONSORTIUM OF INVESTIGATORS OF MODIFIERS OF BRCA1/2 (CIMBA)

CIMBA is a collaborative group of researchers working on genetic modifiers of cancer risk in BRCA1 and BRCA2 mutation carriers. The aim of CIMBA is to provide sufficient sample sizes to allow large-scale studies in order to evaluate reliably the effects of genetic modifiers.

Track Family DNA

Research teams at Roswell Park Comprehensive Cancer Center (where the registry is housed) and across the globe use the data collected by the Familial OCR to seek better methods for detecting, treating, curing and eventually preventing familial ovarian cancer.

Become an Affiliate

Our ongoing work aiding the research of familial ovarian cancer depends upon continued collaboration with research and medical institutions across the country and world that share our mission. To become an affiliate of the registry, contact:

Jasmine Kaur
Registry Director 
(716) 845-4503
Jasmine.Kaur@RoswellPark.org

As an affiliate, your institution or organization may provide any level of partnership, including opportunities such as: 

  • Encouraging your center’s familial ovarian cancer patients and their family members to register their DNA and family history to the registry.
  • Helping to increase awareness of our mission and program.